Because diabetes management in older patients can be complicated by polypharmacy and cognitive impairment, we recently conducted an interventional pilot clinical study which resulted in broadly-perceived improvements in quality of life and cognitive function when we replaced complex anti-diabetic regimens with a single daily dose of fixed combination of insulin degludec and liraglutide (insulin degludec at 100 units/mL and the glucagon-like peptide 1 receptor agonist [GLP-1RA] liraglutide at 3.6 mg/mL) [2]. Here, INS is linked to Cognitive impairment.